[1]叶婧,张以勤,罗浩,等.肾炎康复片改善早期糖尿病肾病血管内皮功能[J].国际内分泌代谢杂志,2014,(04):245-246.[doi:10.3760/cma.j.issn.1673-4157.2014.04.008]
　Ye Jing,Zhang Yiqin,Luo Hao,et al.Effects of Shenyan Kangfu Pian on vascular endothelial function in patients with early diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2014,(04):245-246.[doi:10.3760/cma.j.issn.1673-4157.2014.04.008]
点击复制

肾炎康复片改善早期糖尿病肾病血管内皮功能()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2014年04期
页码:
245-246
栏目:
论著
出版日期:
2014-08-31

文章信息/Info

Title:
Effects of Shenyan Kangfu Pian on vascular endothelial function in patients with early diabetic nephropathy
作者:
叶婧; 张以勤; 罗浩; 王玉新
作者单位：361021　厦门市第二医院肾内科 　　
Author(s):
Ye Jing; Zhang Yiqin; Luo Hao; Wang Yuxin.
Department of Nephropathy，The Second Hospital of Xiamen，Xiamen 361021，China Corresponding author：Wang Yuxin，Email：wyx1000@126.com
关键词:
肾炎康复片; 糖尿病肾病; 内皮素-1; 血栓调节蛋白; 血管内皮生长因子
Keywords:
Shenyan Kangfu Pian; Diabetic nephropathy; Endothelin-1; Thrombomodulin; Vascular endothelial growth factor
DOI:
10.3760/cma.j.issn.1673-4157.2014.04.008
摘要:
目的　探讨肾炎康复片对早期糖尿病肾病患者血浆内皮素-1（ET-1）、血栓调节蛋白（TM）及血管内皮生长因子（VEGF） 水平的影响。方法　入选96例早期糖尿病肾病患者，采用随机数字表法随机分为两组，每组48例，对照组接受常规治疗（阿司匹林肠溶片100 mg/d，qd；阿托伐他汀钙片20 mg/d，qn；厄贝沙坦片150 mg/d，qd；降血糖药物或胰岛素控制血糖，疗程12周）。治疗组在常规治疗基础上加用肾炎康复片治疗（5片/次，3次/d，疗程12周）。ELISA法测定两组患者治疗前、后血浆ET-1、TM及VEGF水平。结果　对照组治疗前血浆ET-1、TM及VEGF水平分别为（58.1±15.2） ng/L、（77.4±15.0） ng/L、（389.8±68.3） ng/L，治疗后均有明显下降，分别为（36.5±9.3） ng/L、（52.3±11.9） ng/L、（227.6±45.9） ng/L（t = 2. 921, 2. 752, 2.818，P ＜0.01）。治疗组治疗前血浆ET-1、TM及VEGF水平分别为（57.3±14.4） ng/L、（78.4±16.2） ng/L、（386.5±66.6） ng/L，治疗后亦均有明显下降，分别为（22.7±7.6） ng/L、（31.2±8.7） ng/L、（157.1±38.2） ng/L（t =2.877、2.699、2.901，P＜0.01）。治疗组下降更为明显，与对照组相比差异有统计学意义（P均＜0.05）。结论　肾炎康复片能降低早期糖尿病肾病患者血浆ET-1、TM及VEGF水平，改善血管内皮功能。
Abstract:
Objective　To explore the effects of Shenyan Kangfu Pian on plasma concentrations of endothelin-1（ET-1），thrombomodulin（TM） and vascular endothelial growth factor（VEGF） in patients with early diabetic nephropathy. Methods　96 patients with early diabetic nephropathy were randomly divided into control group （n =48） and treatment group（n =48）according to a random number table. Patients in control group were treated with routine drugs （aspirin tablet，100 mg/d qd；atorvastatin tablet，20 mg/d qn；irbesartan tablet，150 mg/d qd；oral hypoglycemic agents or insulin）. Patients in treatment group were treated with Shenyan Kangfu Pian（5 tablets，tid） and routine drugs for 12 weeks. Plasma ET-1，TM and VEGF were measured with enzyme linked immunosor-bent assay （ELISA）. Results　The level of plasma ET-1，TM and VEGF in control group were（58.1±15.2）ng/L， （77.4±15.0） ng/L and（389.8±68.3） ng/L before treatment，and were also decreased significantly after treatment [（36.5±9.3）ng/L， （52.3±11.9） ng/L， （227.6±45.9） ng/L，t = 2.921， 2.752， 2.818，P ＜0.01]. The level of plasma ET-1，TM and VEGF in treatment group were （57.3±14.4） ng/L，（78.4±16.2） ng/L and （386.5±66.6） ng/L before treatment，and were also decreased significantly after treatment [（22.7±7.6） ng/L，（31.2±8.7） ng/L，（157.1±38.2） ng/L，t =2.877，2.699，2.901，P＜0.01]. The level of plasma ET-1，TM，VEGF in treatment group were lower than those in control group after treatment（all P＜0.05）. Conclusion　Shenyan Kangfu Pian can improve vascular endothelial cell function by decreasing the level of plasma ET-1，TM and VEGF in patients with early diabetic nephropathy.

参考文献/References:

　[1]　Palmer AJ，Valentine WJ，Chen R，et al.A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA[J].Nephrol Dial Transplant，2008，23（4）：1216-1223. 　
[2]　Broncel M，Koziróg-Kolacińska M，Andryskowski G，et al.Effect of anthocyanins from Aronia melanocarpa on blood pressure， concentration of endothelin-1 and lipids in patients with metabolic syndrome[J].Pol Merkur Lekarski，2007，23（134）：116-119. 　
[3]　Suzuki R，Masaoka H，Hirata Y，et al.The role of endothelin-1 in the origin of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage[J].J Neurosurg，1992，77（1）：96-100. 　
[4]　Marsden PA，Dorfman DM，Collins T，et al.Regulated expression of endothelin 1 in glomerular capillary endothelial cells[J].Am J Physiol，1991，261（1 Pt 2）：F117-F125. 　
[5]　Mather K，Anderson T，Verma S.Insulin action in the vascula-ture：Physiology and pathophysiology[J].J Vasc Res，2001，38（5）：415-422. 　
[6]　Senthil D，Choudhury GG，Mclaurin C，et al.Vascular endothelial growth factor induces protein synthesis in renal epithelial cells：a potential role in diabetic nephropathy[J].Kidney Int，2003，64（2）：468-479. 　
[7]　Hoshi S，Shu Y，Yoshida F，et al.Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats[J].Lab Invest，2002，82（1）：25-35. 　
[8]　刘志红，胡可斌，周虹，等.2型糖尿病肾病患者肾组织中血管内皮细胞生长因子及其受体的变化[J].肾脏病与透析肾移植杂志，2001，10（5）：401-406. 　
[9]　Aso Y，Inukai T，Takemura Y.Mechanisms of elevation of serum and urinary concentrations of soluble thrombomodulin in diabetic patients： possible application as a marker for vascular endothelial injury[J].Metabolism，1998，47（3）：362-365.
[10]　Hirano T，Ookubo K，Kashiwazaki K，et al.Vascular endothelial markers， von Willebrand factor and thrombomodulin index，are specifically elevated in type 2 diabetic patients with nephropa-thy：comparison of primary renal disease[J].Clin Chim Acta，2000，299（1-2）：65-75.
[11]　赵恩俭.我对肾炎的研究与“肾炎康复片”的研制[J].天津中医学院学报，1996，1：1-2.
[12]　邓跃毅，陈以平，唐红，等.肾炎康复片治疗糖尿病肾病的疗效观察[J].中国中西医结合肾病杂志，2005，6（3）：151-153.
[13]　谢席胜，樊均明，李会娟，等.肾炎康复片在肾脏疾病中的应用及评价[J].中国中西医结合肾病杂志，2007，8（8）：493-494.
[14]　胡仲仪，邵世宏，邓跃毅.养阴固肾活血片对肾脏细胞外基质影响的实验研究[J].中国中西医结合肾病杂志，2000，1（3）：144-145.
[15]　Rueckschloss U，Quinn MT，Holtz J，et al.Dose-dependent regulation of NAD（P）H oxidase expression by angiotensin Ⅱ in human endothelial cells：protective effect of angiotensin Ⅱ type 1 receptor blockade in patients with coronary artery disease[J].Arterioscler Thromb Vasc Biol，2002，22（11）：1845-1851.
[16]　Hayashi K，Miyamoto A，Berisha B，et al.Regulation of angiotensin Ⅱ production and angiotensin receptors in microvas-cular endothelial cells from bovine corpus luteum[J].Biol Reprod，2000，62（1）：162-167.

相似文献/References:

[1].2007年糖尿病新进展学习班将举办[J].国际内分泌代谢杂志,2007,(04):226.
[2]李英,段惠军.Raf/MEK/ERK信号转导通路在糖尿病肾病发生发展中的作用[J].国际内分泌代谢杂志,2007,(04):264.
[3]张红 章向成 朱大龙.炎性反应与糖尿病肾病[J].国际内分泌代谢杂志,2015,(01):49.[doi:10.3760/cma.j.issn.1673-4157.2015.01.012]
　Zhang Hong*,Zhang Xiangcheng,Zhu Dalong..Role of inflammation in diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):49.[doi:10.3760/cma.j.issn.1673-4157.2015.01.012]
[4]邵滢,王秋月.Mir-217/Sirt1通路与糖尿病肾病[J].国际内分泌代谢杂志,2015,(02):124.[doi:10.3760/cma.j.issn.1673-4157.2015.02.014]
　Shao Ying,Wang Qiuyue..Mir-217 / Sirt1 pathway and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):124.[doi:10.3760/cma.j.issn.1673-4157.2015.02.014]
[5]王洁,何媛,于珮.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
　Wang Jie*,He Yuan,Yu Pei..Risk factors of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
[6]任慧雯,王秋月.Epac-Rap1与糖尿病肾病[J].国际内分泌代谢杂志,2015,(03):170.[doi:10.3760/cma.j.issn.1673-4157.2015.03.007]
　Ren Huiwen,Wang Qiuyue..Epac-Rap1 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):170.[doi:10.3760/cma.j.issn.1673-4157.2015.03.007]
[7]邵滢,王秋月.MiRNA-150与糖尿病肾病[J].国际内分泌代谢杂志,2015,(03):173.[doi:10.3760/cma.j.issn.1673-4157.2015.03.008]
　Shao Ying,Wang Qiuyue..MiRNA-150 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):173.[doi:10.3760/cma.j.issn.1673-4157.2015.03.008]
[8]陈堃,刘超,陈国芳,等.糖尿病肾病诊断标志物研究进展[J].国际内分泌代谢杂志,2015,(03):176.[doi:10.3760/cma.j.issn.1673-4157.2015.03.009]
　Chen Kun,Liu Chao,Chen Guofang,et al.Urinary biomarkers for diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):176.[doi:10.3760/cma.j.issn.1673-4157.2015.03.009]
[9]任慧雯,王秋月.Vasohibin-1与糖尿病肾病[J].国际内分泌代谢杂志,2015,(04):246.[doi:10.3760/cma.j.issn.1673-4157.2015.04.008]
　Ren Huiwen,Wang Qiuyue..Vasohibin-1 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):246.[doi:10.3760/cma.j.issn.1673-4157.2015.04.008]
[10]安丽,王秋月.Visfatin与胰岛素抵抗及糖尿病肾病的发病机制[J].国际内分泌代谢杂志,2015,(04):248.[doi:10.3760/cma.j.issn.1673-4157.2015.04.009]
　An Li,Wang Qiuyue..Visfatin in the pathogenesis of insulin resistance and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):248.[doi:10.3760/cma.j.issn.1673-4157.2015.04.009]

备注/Memo

备注/Memo:
通信作者：王玉新，Email：wyx1000@126.com
更新日期/Last Update: 2014-07-20